Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. - sprookjes - yvandenbroek - TriplyDB

Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.

Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.

http://www.wikidata.org/entity/Q34413590

about

A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy Coartem: the journey to the clinic Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria The clinical efficacy of artemether/lumefantrine (Coartem)Artemisinin-based combination therapy for treating uncomplicated malaria Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania The safety of artemisinins during pregnancy: a pressing question Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device Cost analysis of school-based intermittent screening and treatment of malaria in Kenya Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Médecins Sans Frontières Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.Treatment with coartem (artemether-lumefantrine) in Papua New Guinea Therapeutic efficacy of Artemether/Lumefantrine (Coartem(R)) against Plasmodium falciparum in Kersa, South West Ethiopia Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study.Progress towards implementation of ACT malaria case-management in public health facilities in the Republic of Sudan: a cluster-sample survey Mobile phone text messaging: tool for malaria control in Africa.Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination Health worker performance in the management of paediatric fevers following in-service training and exposure to job aids in Kenya Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.Primacy of effective communication and its influence on adherence to artemether-lumefantrine treatment for children under five years of age: a qualitative study.Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia Malaria: an update on current chemotherapy.Artemisinin Antimalarials: Preserving the "Magic Bullet"Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.

P2860

Q17485688-CD26942A-E354-4753-AF0B-326D4ABC0E9E Q21034131-FC2DCCBC-94EB-4E4B-89B0-2FC7D8E01F31 Q21034136-F8A4438D-31D6-4689-AB19-A9C86AD1B5AE Q21034141-89A77879-4E0D-478B-9C4C-94440CC1C399 Q24241785-6A0D29A1-F89B-44FB-A74E-803F3F54078C Q24245437-2621A3B3-A384-42BC-96ED-8C5A44386738 Q24246332-92641D72-7818-4982-8207-D23D4C21AB7E Q24810617-04F6BCA2-1637-45DA-A6A4-3909256763DE Q26783646-78ED1203-4835-4006-B686-809DC2FF035D Q26820807-D7BB71F3-E7C3-4EF7-88DF-B4C94DB096A1 Q27497231-03580B78-C911-4D4B-88C8-3BBD7099F3A9 Q28469217-6D5AF944-8FF3-431B-B4F4-246E5183B971 Q28469347-A3730F2F-DF44-49AE-88E8-CEF2E4556B4A Q28472182-455E9A1D-DE71-4FD6-8B23-610F772C2221 Q28538749-ED4BD76C-C966-4EA6-8E3F-B44351A7652F Q28546804-EAADC26D-5C17-4CA1-8853-40F8BD8EA2CB Q28744234-6C567FCB-1504-4764-9CF9-01A8D1D601CA Q30397022-C48D9FEC-22D8-4E61-95F3-577B0D8F6699 Q33251914-43F6F505-7FE4-4AB5-B61A-1A6E86EF2E73 Q33276757-2943C9C3-ED8D-46E0-A5D4-0270853CBEEE Q33342827-5D92EEB3-1557-4273-8D6F-0E8A5F795AB1 Q33358271-9083C1A1-E186-4C4D-9D10-E32EF47FCE02 Q33385477-004C9BE7-9C00-4B13-9473-E3536B3BEBC8 Q33635019-52A5B765-0300-4295-A601-B125BFF7F9E8 Q33676088-5C560716-9694-4272-BB6E-B936FF65B91B Q33733033-0BDD10D7-D06A-40B2-B85D-3FE5C0DD45CD Q33749688-4AB33930-DD5B-4E2D-BB9E-8A0D5155E48C Q33895092-75A506B7-F2D7-4F88-A71E-15BCB9164FF2 Q34055721-9B6F9044-B98D-481C-B2AD-FEADA08424B5 Q34119570-843A47CC-25BC-44AB-A77F-36096939B408 Q34169722-46F4BA30-E9B0-4092-A328-E991EB760FA3 Q34177472-E55CDDE6-4D30-44C5-A438-F5FA62F4DDA6 Q34203206-9B640AC9-06AE-4884-88D5-FAFAEB90C1E5 Q34290067-B23D1582-5239-4994-9DBC-0D7EFDB99B85 Q34298037-43E69CFF-7BAF-4924-B59F-FCA70D4EB061 Q34422288-EBD9621D-5B10-4D78-AF9D-49AB0A563852 Q34433106-95D11C87-B80A-4BB8-A533-B630E475DBA2 Q34622342-59F3B70A-F134-430C-9B24-35C54F7CE496 Q34629332-340D66B0-0C01-451F-A57F-81EC3F8F98AB Q34662803-BC80F57A-6629-43B0-BE3F-E2776041A34F

P2860

Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.

http://www.wikidata.org/entity/Q34413590

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@ast

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@en

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@nl

type

label

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@ast

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@en

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@nl

prefLabel

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@ast

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@en

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@nl

P1433

Q34413590-EC9817D7-E327-448F-A20A-A8D388C7F254

P1476

Q34413590-B5DD6712-D6CE-492E-990B-28260991A1D7

P2093

Q34413590-23440509-1AF5-46CD-BE7F-80C59D43190A

Q34413590-411AA11B-3B5F-4BF7-B6BE-1EB4267C1B3C

Q34413590-459300EF-CF14-4904-83EE-F16C5426898C

Q34413590-47537413-FF3A-44F4-A0A5-E80D0DB3AA6D

Q34413590-5191B1C7-145B-47C4-98C4-F512DF3D504F

Q34413590-74114C3B-144A-493F-A4CA-5E15329323F4

Q34413590-88F171FB-5686-44E2-9E11-DC0F40920F80

Q34413590-ABDFC17F-C50A-4600-8A50-225872F7987B

Q34413590-BBAAFC88-A030-4875-AC40-7C8F86F48220

Q34413590-D03A3FF5-6D5B-4831-B7B6-88F69589070A

P304

Q34413590-5F3B5F8F-025F-44DC-A0EE-24EC5BE9B6FB

P31

Q34413590-689D7B46-58F1-4E08-B1FE-16E035592C4E

P356

Q34413590-8B4BC275-2263-46F6-ACD9-04696DE9EF6F

P407

Q34413590-30D0F293-1AC3-4A7F-B38E-CBA9CC9F2C4C

P433

Q34413590-A889A6F5-30BD-4BD5-9735-101CDA126640

P478

Q34413590-563B6CC1-C03B-4AE5-9792-FF0C488BFF49

P50

Q34413590-0B4E6C98-9D65-4D80-99BD-5DBDF711858F

Q34413590-14C50554-043B-4DE7-9B4D-48987704CF24

P577

Q34413590-25FE3482-3400-480D-879A-C992E6BFAA3F

P5875

Q34413590-0D9B571D-F9F5-4D2E-8AE4-100C525B7ACE

P698

Q34413590-E7BF60CE-CD2B-462B-B3CA-D2EE4C8357D3

P921

Q34413590-62623982-9A5C-4CE5-A048-D1F0DAF27D61

Q34413590-71A04564-612E-4283-BD9E-315E04341F1A

Q34413590-FE3944AD-5463-44C1-9DF0-F3B6C953D336

P356

S0140-6736(05)66416-1

P1433

P1476

Supervised versus unsupervised ...... a, Uganda: a randomised trial.

@en

P2093

Carole Fogg

http://www.w3.org/2001/XMLSchema#string

Eugene Ruzagira

http://www.w3.org/2001/XMLSchema#string

Francesco Checchi

http://www.w3.org/2001/XMLSchema#string

Francis Bajunirwe

http://www.w3.org/2001/XMLSchema#string

Isaac Kigozi

http://www.w3.org/2001/XMLSchema#string

James Kiguli

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Guthmann

http://www.w3.org/2001/XMLSchema#string

Joseph Babigumira

http://www.w3.org/2001/XMLSchema#string

Juliet Kyomuhendo

http://www.w3.org/2001/XMLSchema#string

Laurent Ferradini

http://www.w3.org/2001/XMLSchema#string

P304

1467-1473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(05)66416-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9469

http://www.w3.org/2001/XMLSchema#string

P478

365

http://www.w3.org/2001/XMLSchema#string

P50

Francis Bajunirwe

Francesco Grandesso

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7886496

http://www.w3.org/2001/XMLSchema#string

P698

15850630

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum